Lynparza Partners AZ And Merck & Co Target US Breast Cancer Market

 
• By John Davis

AstraZeneca and Merck & Co's strategic collaboration on the development of olaparib and other anticancers has the US breast cancer sector in its sights, with approval of a US sNDA in the indication expected in early 2018.

Stamp
• Source: Shutterstock

More from New Products

More from Scrip